About SeQuent
SeQuent is a publicly listed company based in Bengaluru (India) founded in 2002, and was acquired by The Carlyle Group in May 2020. APIs are developed and manufactured for therapeutic areas. The company has 1,430 employees. SeQuent has completed 1 acquisition, including Indo Phyto Chemicals. SeQuent offers products and services including APIs, FDFs, and Analytical Services. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its legal entity in India is SeQuent Scientific Limited (U24110MH2002PLC136868). Its competitors include Laurus Labs, Symbiotec and Jubilant Pharma; 2 of its 3 listed competitors have raised funding.
Company details
SeQuent was established in 2002 in Bengaluru, India, focusing on the pharmaceutical sector. Active pharmaceutical ingredients (APIs) are produced for various therapeutic areas through three manufacturing facilities located in Karnataka and Maharashtra. Contract research services are provided by its research arm, SeQuent Research Limited, specializing in analytical and bioanalytical support for API, pharmaceutical, personal care, and nutraceutical companies.
- Headquarters Bengaluru, India
- Employees 1,430
- Stage Acquired
- SectorsHealthcare
- Website sequent.in
- Social LinkedIn X Facebook
- Acquired by The Carlyle Group (May 2020)
- Legal Name Sequent Scientific Limited
- Annual Revenue$364.51 M (USD)13.75as on Mar 31, 2026
- Net Profit$18.87 M (USD)663.53as on Mar 31, 2026
- EBITDA$70.02 M (USD)66.74as on Mar 31, 2026
- InvestorsThe Carlyle Group
& 3 more
- Employee Count1,430
- Investments & Acquisitions
- Acquired byThe Carlyle Group
(May 2020)
Associated legal entities of SeQuent
SeQuent is associated with 2 registered companies on The Company Check; the primary company is Sequent Scientific Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Sequent Scientific Limited CIN U24110MH2002PLC136868 | Amalgamated | 16 Aug 2002 | Navi Mumbai, Maharashtra | 5 | View details | ||
| Sequent Research Limited CIN U24232TS2007PLC196886 | Amalgamated | 13 Apr 2007 | Hyderabad, Telangana | ₹9.5 Cr | 52 | 4 | View details |
Products & Services of SeQuent
SeQuent offers a comprehensive portfolio of products and services, including APIs, FDFs, and Analytical Services.
Active ingredients for veterinary medications
Finished dosage forms for animal health care
Testing and analysis for animal health products
Funding Insights of SeQuent
- Total Rounds 3
- First Round $31.54M
(Apr 2014)
- Investors Count 2
All 3 funding rounds of SeQuent with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | Post-IPO | – | – | ||
| May 2015 | $627.84M | Post-IPO | – | – | – |
| Apr 2014 | $31.54M | Post-IPO | – | – |
3 investors in total: 3 institutional.
Investors in SeQuent
SeQuent has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include The Carlyle Group, Ascent Capital and Convergent Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
AscentCapital is engaged in potato farming, grain marketing, and equipment services in Maine. | 2000 | ascentcapital.in | Bengaluru, India | |
Private equity investments are directed toward multiple sectors. | 1986 | carlyle.com | ||
| convergentfinance.com |
Investor details for SeQuent
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Sequent Scientific Limited (SeQuent)
Sequent Scientific Limited is the primary company behind SeQuent. The boards of the 2 registered companies of SeQuent currently have 9 directors; the longest-serving is Arun Kumar Pillai, appointed in 2002. 16 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Arun Kumar Pillai DIN 00084845 | Director | 16 Aug 2002 | 24 yrs 2 mo | Sequent Scientific Limited |
| Kannan Natraj Sharma DIN 00408118 | Director | 31 Mar 2006 | 20 yrs 7 mo | Sequent Scientific Limited |
| Pallipuram Mathai Thampi DIN 00114522 | Director | 31 Dec 2007 | 18 yrs 10 mo | Sequent Scientific Limited |
| Deepak Calian Vaidya DIN 00337276 | Director | 31 Dec 2007 | 18 yrs 10 mo | Sequent Scientific Limited |
| K R Ravishankar DIN 00084908 | Director | 01 Mar 2008 | 18 yrs 8 mo | Sequent Scientific Limited |
| Rajaram Narayanan DIN 02977405 | Director | 11 Apr 2022 | 4 yrs 7 mo | Sequent Research Limited |
| Prasad Sitaram Lad DIN 09597006 | Director | 24 May 2022 | 4 yrs 5 mo | Sequent Research Limited |
| Saurav Bhala DIN 10490964 | Director | 13 Feb 2024 | 2 yrs 9 mo | Sequent Research Limited |
| Vedprakash Shantalingappa Ragate DIN 10578409 | Director | 11 Apr 2024 | 2 yrs 7 mo | Sequent Research Limited |
People of SeQuent
34 people are tracked at SeQuent (16 in leadership, 18 in team); the tracked headcount is 1,430.
| Name | Role | Group |
|---|---|---|
Mayank Shah | Head Taxation | Leadership |
Malleswara Rao | Head-regulatory Affairs | Leadership |
Sanjay Vaishnav | Vice President Operations | Leadership |
Saurabh Sheela Vasant Chambhare | Head Strategic Planning & Operations | Leadership |
| Group Head Human Resources | Leadership | |
Sharat Narasapur | Jt. Managing Director | Leadership |
Ca | Group Chief Financial Officer - Global Operations | Leadership |
Rahul Dev | Assistant General Manager (legal) | Leadership |
| CEO, Managing Director | Leadership | |
Phillip Trott | Head - Legal, Secretarial, Compliance, CSR & Chief Risk Officer | Leadership |
Parag Maheshwary | Associate Vice President- Sequent Scientific Limited (carlyle Portfolio Company) | Leadership |
Srinivas Churya A | Head Analytical | Leadership |
Sameer Chawnekar | Chief Information Officer - Global Operations | Leadership |
Ranjit Suryawanshi | Site Head | Leadership |
Ajay Palekar | Head Of Supply Chain Management | Leadership |
| Executive Director | Leadership | |
Nithin Salian | Deputy Manager IT And Analytical Quality Assurance | Team |
Sangeetha Dsouza | Analyst At Analytical Service Department | Team |
Avinash Patil | Human Resources Generalist | Team |
Priyanka Kumari | Sr. Manager- Project Management | Team |
14 more people are available in the full profile.
Complete people profiles for SeQuent
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of SeQuent
SeQuent is a publicly listed company on the NSE with ticker symbol SEQUENT in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Mar 2016
- Listed onNSE: SEQUENT
- Listed entitySequent Scientific Limited
- Exchange sectorHealth technology
- ISININE807F01027
- Share price₹201.17 (+3.71% on the day) · 2026-01-22
- Market capitalisation₹5,067 Cr
- Price to earnings121.9
- EPS (diluted, trailing year)₹1.65
- Volume (last session)364,240
- Analyst consensusNeutral
Financials of SeQuent
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | ₹3,420 Cr | ₹177 Cr | ₹657 Cr |
| 2024 | ₹3,007 Cr | ₹23.2 Cr | ₹394 Cr |
| 2023 | ₹1,368 Cr | -₹35.9 Cr | ₹64.9 Cr |
| 2022 | ₹1,419 Cr | -₹121 Cr | ₹46.0 Cr |
| 2021 | ₹1,412 Cr | ₹41.3 Cr | ₹86.7 Cr |
Balance sheet, profit and loss, cash flow and ratios of Sequent Scientific Limited are on its company page.
Detailed financial statements for SeQuent
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SeQuent
SeQuent has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Indo Phyto Chemicals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Manufacturer & supplier of active pharmaceutical ingredients | indophytochemicals.com | Delhi, India | 1978 | Jan 2016 | •••• |
Complete acquisition details for SeQuent
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of SeQuent
6 dated milestones of SeQuent across 18 years, from founding to its latest funding, stage changes and deals.
- Founded SeQuent is founded.
- Funding First funding round of $31.5M.
- Acquisition Acquires Indo Phyto Chemicals.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by The Carlyle Group.
- Funding Latest funding round, Post-IPO,.
Competitors of SeQuent
SeQuent has 3 listed competitors in our database, 2 of them funded. They include Laurus Labs, Symbiotec and Jubilant Pharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| jubilantpharma.com | 1978 | Noida, India | Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. |
Detailed competitors of SeQuent
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SeQuent
The website of SeQuent (sequent.in) receives about 5K visits a month.
- Monthly visits5K
▼ 0.6% vs previous month
Websites whose visitors overlap most with SeQuent. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| shipindia.com | 100% | 126.6K | #334,847 | View details | |
| wartsila.com | 100% | 495.3K | #94,925 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as SeQuent (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sequent
Complete news archive for SeQuent
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SeQuent
SeQuent was founded in 2002 and raised its 1st funding round 12 years after it was founded.
SeQuent is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
SeQuent has 1,430 employees.
Annual revenue of SeQuent is $364.51M as on Mar 31, 2026.
SeQuent was established in 2002 in Bengaluru, India, focusing on the pharmaceutical sector. Active pharmaceutical ingredients (APIs) are produced for various therapeutic areas through three manufacturing facilities located in Karnataka and Maharashtra. Contract research services are provided by its research arm, SeQuent Research Limited, specializing in analytical and bioanalytical support for API, pharmaceutical, personal care, and nutraceutical companies.
SeQuent's top competitors include Laurus Labs, Symbiotec and Jubilant Pharma.
SeQuent offers APIs, FDFs, and Analytical Services.
Yes, SeQuent is publicly traded on NSE under the ticker symbol SEQUENT.
SeQuent has made 1 acquisition, including Indo Phyto Chemicals.
SeQuent has 3 investors. Key investors include The Carlyle Group, Ascent Capital, and Convergent Finance.
SeQuent is associated with 2 legal entities: Sequent Scientific Limited, Sequent Research Limited.
Yes. SeQuent was acquired by The Carlyle Group in May 2020.